Posted by Michael Wonder on 03 Jan 2022
FDA grants ILiAD Biotechnologies fast track designation for next generation pertussis vaccine BPZE1
3 January 2021 - ILiAD Biotechnologies, today announced that the U.S. FDA has granted fast track designation to BPZE1, a next generation vaccine for active booster immunisation against pertussis.
BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development.
